Oxytocin: research reference

Record the receptor panel actually measured. Absence of a result for another receptor does not establish absence of activity.

In in vitro studies, oxytocin activates signaling through Gq and members of the Gi/o family via its receptor. Its binding domain shares homology with vasopressin V1a, V1b and V2 receptors, consistent with the cross-affinity described in vitro.

The purity value is a product-label specification, not an assay result. A batch result can only be asserted from that batch’s certificate.

These names help identify the catalog entry. A descriptive label is not evidence of efficacy, and structural identity still requires appropriate documentation.

Hypothalamic nonapeptide

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Personal protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

This record’s oxytocin is a nonapeptide with a disulfide bond between its two cysteines. A 2007 chemistry study separately examined that structure and its reduced oxytocin-dithiol form. Sharing an amino-acid sequence does not make the preparations analytically equivalent.

The study investigated transformation of the reduced form using chromatographic and spectrometric characterization. Identifying the tested form is essential: oxytocin alone can conceal differences between starting material and observed products. Sources: PMID 17692543.

An in vitro bioluminescence-resonance-energy-transfer biosensor study found that oxytocin activated Gq and several Gi/o-family members through its receptor. It measured molecular interactions in a defined cellular system, not behavior or catalog-product performance.

Included analogs showed different signaling profiles. One pathway does not summarize the entire receptor, and preserving those differences distinguishes oxytocin from derivatives designed to explore particular responses. Sources: PMID 22069312.

A 2013 publication compared oxytocin, vasopressin and analogs in vitro at mouse OTR, V1a and V1b receptors, separating binding experiments from intracellular-signaling readings. These address where a compound binds and what response follows.

Some analogs showed greater OTR selectivity than natural ligands in that system. Their findings must not be assigned automatically to oxytocin. Receptor species, comparators and measured variable belong in any selectivity claim. Sources: PMID 23723434.

An accelerated-degradation study examined aqueous oxytocin under different acidity and temperature conditions. Complementary methods identified deamidation, extra-sulfur species, dimers and aggregates. Loss of intact molecule alone does not identify what formed instead.

These are experimental aqueous formulations. Findings do not automatically establish a commercial lyophilizate’s expiry or the stability of every solution made from it. Alkaline degradation is also not equivalent to clean chemical reduction of the disulfide bond. Sources: PMID 19343484.

Another study investigated degradation routes using oxytocin, analogs and isotope-labeled materials. Mass spectrometry and nuclear magnetic resonance supported proposed intermediates and dimeric products. The mechanism belongs to those preparations rather than every sample.

Separate declared identity, batch analytical results and degradation literature when reading vial documentation. A paper identifies questions and possible chemical species; it does not prove those species are present or absent in commercial material. Sources: PMID 23868209.